Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 2,733 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Carcinoma Clear all
Completed Phase 1 Interventional

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

NCT02639026
View directory record Official record
Conditions
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions
Radiotherapy, MEDI4736, Tremelimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

NCT01387555
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Biological · Other
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
La Jolla, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Withdrawn Not applicable Interventional

Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis

NCT01710293
View directory record Official record
Conditions
Lung Cancer, Bladder Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Breast Cancer
Interventions
Communication of Patients Lost to Follow-up to Providers
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Chicago, Illinois • Hines, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

NCT06052852
View directory record Official record
Conditions
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma
Interventions
BDC-3042, Cemiplimab
Drug
Lead sponsor
Bolt Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

NCT00016198
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Prologue Research International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
74
States / cities
Tucson, Arizona • Pine Bluff, Arkansas • Covina, California + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 29, 2026, 4:21 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

NCT07903415
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
PF-08098488
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Not applicable Interventional Results available

Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer

NCT00769652
View directory record Official record
Conditions
Lung Cancer, Malnutrition, Pancreatic Cancer, Prostate Cancer, Weight Changes
Interventions
Medical nutrition therapy, Standard Care
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 1Phase 2 Interventional

SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

NCT00361244
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
SU011248, Irinotecan, Cetuximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

NCT01941316
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
Interventions
Carfilzomib, Irinotecan
Drug
Lead sponsor
Cancer Research and Biostatistics Clinical Trials Consortium
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Goodyear, Arizona • Lexington, Kentucky • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional

Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer

NCT00417287
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
PX-12
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 29, 2026, 4:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT05379985
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Interventions
RMC-6236
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
21
States / cities
Orange, California • Santa Monica, California • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional

Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer

NCT01198535
View directory record Official record
Conditions
Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Cetuximab, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

NCT01931150
View directory record Official record
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

NCT00767468
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Not applicable Interventional Results available

Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET

NCT01065818
View directory record Official record
Conditions
Esophageal Cancer, Non-small Cell Lung Cancer
Interventions
Fluoro-L-Thymidine
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Not applicable Interventional Results available

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

NCT03154190
View directory record Official record
Conditions
Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
Interventions
Best Practice, Laboratory Biomarker Analysis, Supportive Care, Survey Administration
Other · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 29, 2026, 4:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeted Navigation in Hepatocellular Carcinoma (HCC)

NCT06260943
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatobiliary Cancer
Interventions
Target Navigation Pilot Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening

NCT04607291
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Community Health Service, Survey Administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

NCT03875313
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions
CB-839, Talazoparib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 29, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 29, 2026, 4:21 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

NCT06251973
View directory record Official record
Conditions
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Cancer, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Esophageal Cancer, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
AgenT-797, Botensilimab, Balstilimab, Ramucirumab, Paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 29, 2026, 4:21 PM EDT